{"id":1068391,"date":"2022-10-27T01:56:06","date_gmt":"2022-10-27T05:56:06","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/rain-therapeutics-announces-a-poster-presentation-at-the-34th-eortc-aacr-nci-symposium\/"},"modified":"2024-08-18T11:46:39","modified_gmt":"2024-08-18T15:46:39","slug":"rain-therapeutics-announces-a-poster-presentation-at-the-34th-eortc-aacr-nci-symposium","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/rain-therapeutics-announces-a-poster-presentation-at-the-34th-eortc-aacr-nci-symposium.php","title":{"rendered":"Rain Therapeutics Announces a Poster Presentation at the 34th EORTC\/AACR\/NCI Symposium"},"content":{"rendered":"<p><![CDATA[NEWARK, Calif., Oct.  26, 2022  (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (\u201cRain\u201d), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the 34th EORTC\/AACR\/NCI Symposium taking place on October 26-28, 2022 in Barcelona, Spain.]]><\/p>\n<p>Here is the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/10\/26\/2542176\/0\/en\/Rain-Therapeutics-Announces-a-Poster-Presentation-at-the-34th-EORTC-AACR-NCI-Symposium.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Rain Therapeutics Announces a Poster Presentation at the 34th EORTC\/AACR\/NCI Symposium\">Rain Therapeutics Announces a Poster Presentation at the 34th EORTC\/AACR\/NCI Symposium<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here is the original post: Rain Therapeutics Announces a Poster Presentation at the 34th EORTC\/AACR\/NCI Symposium <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/rain-therapeutics-announces-a-poster-presentation-at-the-34th-eortc-aacr-nci-symposium.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068391","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068391"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068391"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068391\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}